Patent Prosecution: Law, Practice, and Procedure, 8th Ed, 2014 Supplement

The 2014 Supplement covers recent important decisions including the Supreme Court s decision in Association for Molecular Pathology v. Myriad Genetics Inc., which held that isolated deoxyribonucleic acid (DNA) is an unpatentable product of nature, while cDNA is a non-naturally occurring genetic sequence and is patent eligible. The Supplement covers Federal Circuit decisions in: Accenture Global Services v. Guidewire Software, Inc. (a system claim reciting computer-implemented insurance function was not patent eligible) Hamilton Beach Brands, Inc. v. Sunbeam Products, Inc. (the on-sale bar applies to an offer made by the patentee s own supplier) Pronova Biopharma Norge v. Teva Pharmaceuticals (rejecting the argument that a public use of a pharmaceutical formulation requires use in treating a medical condition) It also discusses the Patent Trial and Appeal Board s holding In re Erol; the Act to Correct and Improve Certain Provisions of the Leahy-Smith America Invents Act; the Patent Law Treaties Implementation Act of 2012; and Patent Office Examination Guidelines for Implementing the First Inventor to File Provisions of the Leahy-Smith America Invents Act.